(0.31%) 5 115.66 points
(0.32%) 38 361 points
(0.33%) 15 981 points
(-0.94%) $83.06
(5.51%) $2.03
(0.36%) $2 355.60
(0.41%) $27.65
(4.00%) $959.00
(-0.23%) $0.933
(-0.39%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering...
Stats | |
---|---|
本日の出来高 | 1.31M |
平均出来高 | 2.25M |
時価総額 | 14.90M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $-0.620 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.00100 (0.57%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 1 903 680 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 235 320 | Stock Option |
2024-02-27 | Saenger Bradley | Buy | 282 000 | Stock Option |
INSIDER POWER |
---|
99.09 |
Last 97 transactions |
Buy: 77 144 979 | Sell: 389 187 |
ボリューム 相関
Tonix Pharmaceuticals 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Tonix Pharmaceuticals 相関 - 通貨/商品
Tonix Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $7.77M |
総利益: | $-1.26M (-16.27 %) |
EPS: | $-6.85 |
FY | 2023 |
収益: | $7.77M |
総利益: | $-1.26M (-16.27 %) |
EPS: | $-6.85 |
FY | 2022 |
収益: | $0 |
総利益: | $-112.09M (0.00 %) |
EPS: | $-20.11 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.976 |
Financial Reports:
No articles found.
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。